Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04194944 · OUTCOME

PFS2 (With Pembrolizumab)

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer · Source last updated 2025-10-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Baseline to Second Disease Progression or Death from Any Cause Up to 38 Months

What was measured

PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death from any cause in the absence of observed disease progression.

Analysis population: ITT Pembrolizumab: Participants included in the ITT population who were stratified with the intent to receive pembrolizumab in the event of the control-arm assignment. Participants censored: TRT A: 103; TRT B: 62

Groups in this outcome

Selpercatinib (TRT A)

160 mg Selpercatinib administered orally BID continuously in 21-day cycles.

Pemetrexed and Platinum With Pembrolizumab (TRT B)

Pemetrexed 500 mg/m2, IV on Day 1 Q3W plus investigator's choice of carboplatin AUC 5 (maximum dose 750 mg\] IV) or cisplatin 75mg/m2, IV on Day 1 Q3W for 4 cycles, plus investigator's choice with 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Selpercatinib (TRT A)129
Pemetrexed and Platinum With Pembrolizumab (TRT B)83

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Selpercatinib (TRT A)NANot reportedNANAData not available due to high censoring.
Pemetrexed and Platinum With Pembrolizumab (TRT B)NANot reportedNANAData not available due to high censoring.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Data not available due to high censoring.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
      2. comment
        Data not available due to high censoring.
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      129
    2. group Id
      OG001
      value
      83
    units
    Participants
description
PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death from any cause in the absence of observed disease progression.
dispersion Type
95% Confidence Interval
groups
  1. description
    160 mg Selpercatinib administered orally BID continuously in 21-day cycles.
    id
    OG000
    title
    Selpercatinib (TRT A)
  2. description
    Pemetrexed 500 mg/m2, IV on Day 1 Q3W plus investigator's choice of carboplatin AUC 5 (maximum dose 750 mg\] IV) or cisplatin 75mg/m2, IV on Day 1 Q3W for 4 cycles, plus investigator's choice with 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.
    id
    OG001
    title
    Pemetrexed and Platinum With Pembrolizumab (TRT B)
param Type
MEDIAN
population Description
ITT Pembrolizumab: Participants included in the ITT population who were stratified with the intent to receive pembrolizumab in the event of the control-arm assignment. Participants censored: TRT A: 103; TRT B: 62
reporting Status
POSTED
time Frame
Baseline to Second Disease Progression or Death from Any Cause Up to 38 Months
title
PFS2 (With Pembrolizumab)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice